BioMarin Pharmaceutical (BMRN) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic transformation, growth outlook, and priorities

• Achieved a 15% CAGR over two years, with preliminary FY'25 revenue at $3.2B and Voxzogo revenue at $920M, reflecting 27% year-over-year growth.

• Significant cost reductions of $500M identified, and profitability increased over 3x compared to topline growth in FY'24, with $728M operating cash flow Q3'25 YTD.

• Two M&A deals in 2025, including the $4.8B Amicus acquisition expected to close in Q2'26, to diversify and accelerate revenue growth and expand the portfolio with Galafold and Pombiliti.

• Targeting sustained double-digit long-term revenue CAGR into the 2030s, leveraging internal innovation and external business development.

• Near-term focus on deleveraging and long-term strategy to supplement the pipeline with earlier-stage deals.

Pipeline, R&D catalysts, and product highlights

• Multiple Phase 3 data readouts expected in 2026, including BMN 351 (Duchenne muscular dystrophy), BMN 333 (long-acting CNP for achondroplasia), and BMN 401 for ENPP1 deficiency.

• Voxzogo is progressing toward full FDA approval, supported by over 10,000 patient-years of safety data and robust efficacy endpoints, and remains the only approved therapy for achondroplasia in infants.

• Expansion into new indications for Voxzogo and label expansions for other therapies, including PALYNZIQ for adolescents and hypochondroplasia, are anticipated within the next 12 months.

• Pombiliti + Opfolda and Galafold, acquired via Amicus, represent $1B peak revenue opportunities each, with global expansion plans.

• The R&D strategy emphasizes both internal development and external innovation to maintain a catalyst-rich pipeline.

Market position, competition, and intellectual property

• Voxzogo maintains high adherence rates (~90%) and is the only approved precision therapy for infants and children with achondroplasia, with robust efficacy and safety data.

• Strategies to defend market position include vigorous IP protection, orphan drug exclusivity, and ongoing litigation in the US and Europe, with key decisions expected in 2026.

• The company expects some patient switching as new competitors enter, but emphasizes long-term safety, efficacy, and established data as key retention drivers.

• Building global capabilities and reputation over 20 years has created significant barriers to entry for competitors.